Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer

• Published in: Blood Vol. 122; no. 7; pp. 1105 - 1113
• Main Authors: Zhang, Hua, Maric, Irena, DiPrima, Michael J., Khan, Javed, Orentas, Rimas J., Kaplan, Rosandra N., Mackall, Crystal L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.08.2013; American Society of Hematology
• Subjects: Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Blotting, Western; Cell Differentiation; Cell Proliferation; Cells, Cultured; Child; Fibroblasts - immunology; Fibroblasts - pathology; Flow Cytometry; GATA3 Transcription Factor; Gene Expression Profiling; Human Umbilical Vein Endothelial Cells; Humans; Immunophenotyping; Immunosuppression; Interleukin-4 - pharmacology; Lipopolysaccharide Receptors; Lymphocyte Activation; Lymphocytes - immunology; Lymphocytes - pathology; Monocytes - immunology; Monocytes - pathology; Myeloid Cells - immunology; Myeloid Cells - pathology; Oligonucleotide Array Sequence Analysis; Plenary Paper; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma - blood; Rhabdomyosarcoma - immunology; Rhabdomyosarcoma - pathology; RNA, Messenger - genetics; Sarcoma, Ewing - blood; Sarcoma, Ewing - immunology; Sarcoma, Ewing - secondary; Th2 Cells; Tumor Escape - immunology

Fibrocytes are hematopoietic stem cell–derived fibroblast precursors that are implicated in chronic inflammation, fibrosis, and wound healing. Myeloid-derived suppressor cells (MDSCs) expand in cancer-bearing hosts and contribute to tumor immune evasion. They are typically described as CD11b+HLA-DR–...